CN118647379A - 用于治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案 - Google Patents

用于治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案 Download PDF

Info

Publication number
CN118647379A
CN118647379A CN202280090883.2A CN202280090883A CN118647379A CN 118647379 A CN118647379 A CN 118647379A CN 202280090883 A CN202280090883 A CN 202280090883A CN 118647379 A CN118647379 A CN 118647379A
Authority
CN
China
Prior art keywords
cancer
alkyl
bid
combination
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280090883.2A
Other languages
English (en)
Chinese (zh)
Inventor
L·安德斯
J·李
林敦敦
T·L·瓦纳尔代尔
韦萍
杨静
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN118647379A publication Critical patent/CN118647379A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280090883.2A 2021-12-02 2022-12-01 用于治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案 Pending CN118647379A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163285457P 2021-12-02 2021-12-02
US63/285457 2021-12-02
PCT/IB2022/061652 WO2023100134A1 (en) 2021-12-02 2022-12-01 Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer

Publications (1)

Publication Number Publication Date
CN118647379A true CN118647379A (zh) 2024-09-13

Family

ID=84462534

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280090883.2A Pending CN118647379A (zh) 2021-12-02 2022-12-01 用于治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案

Country Status (12)

Country Link
US (1) US20250041277A1 (cg-RX-API-DMAC10.html)
EP (1) EP4440575A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024544625A (cg-RX-API-DMAC10.html)
KR (1) KR20240112932A (cg-RX-API-DMAC10.html)
CN (1) CN118647379A (cg-RX-API-DMAC10.html)
AU (2) AU2022402512A1 (cg-RX-API-DMAC10.html)
CA (1) CA3241001A1 (cg-RX-API-DMAC10.html)
IL (1) IL312980A (cg-RX-API-DMAC10.html)
MX (1) MX2024006747A (cg-RX-API-DMAC10.html)
TW (1) TWI873485B (cg-RX-API-DMAC10.html)
WO (1) WO2023100134A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202404615B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
EP4604961A1 (en) * 2022-10-18 2025-08-27 Pfizer Inc. Compounds for the treatment of cancer
EP4719405A1 (en) * 2023-06-02 2026-04-08 Pfizer Inc. Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
WO2025202871A1 (en) * 2024-03-27 2025-10-02 Pfizer Inc. Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor
WO2025202854A1 (en) * 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
WO2026133192A1 (en) * 2024-12-20 2026-06-25 Pfizer Inc. Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
CN118286225A (zh) 2018-04-26 2024-07-05 辉瑞公司 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
CA3128155C (en) 2019-01-31 2023-09-19 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2

Also Published As

Publication number Publication date
AU2026201311A1 (en) 2026-03-12
IL312980A (en) 2024-07-01
MX2024006747A (es) 2024-06-19
US20250041277A1 (en) 2025-02-06
KR20240112932A (ko) 2024-07-19
TW202332431A (zh) 2023-08-16
ZA202404615B (en) 2025-12-17
TWI873485B (zh) 2025-02-21
WO2023100134A1 (en) 2023-06-08
CA3241001A1 (en) 2023-06-08
EP4440575A1 (en) 2024-10-09
AU2022402512A1 (en) 2024-06-20
JP2024544625A (ja) 2024-12-03

Similar Documents

Publication Publication Date Title
US12263141B2 (en) Methods for treating cancer
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
JP7671327B2 (ja) 消化管間質腫瘍の治療のための併用療法
CN107864625B (zh) 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品
CN106470696B (zh) 用于治疗癌症的药物组合
US20240000783A1 (en) Combination therapy
JP2018512403A (ja) 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリン類の使用
CN112533610B (zh) 用于治疗腺样囊性癌的包含双氟烷基-1,4-苯并二氮杂䓬酮化合物的组合物
TW201217361A (en) Method of treating abnormal cell growth
JP2025087716A (ja) 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート
TW202329946A (zh) 用於治療癌症之方法及包含cdk2抑制劑之給藥方案
CN105283178A (zh) 用于治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合
WO2021154976A1 (en) Methods of treating brain cancer with panobinostat
JP2025509278A (ja) 小細胞肺癌を治療する方法
CN113329749A (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
RU2849370C1 (ru) Способы и схемы дозирования, содержащие ингибитор cdk2 и ингибитор cdk4, для лечения рака
HK40116611A (en) Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
US11684672B2 (en) Combinations of copanlisib with anti-PD-1 antibody
IT202100009926A1 (it) Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4
WO2021048419A1 (en) Combination therapies comprising trametinib for the treatment of cholangiocarcinoma
EP4027996A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
US20240382495A1 (en) Combinations of copanlisib with anti-pd-1 antibody
CA2984357C (en) Methods for treating cancer
HK40096012A (en) Combination therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40116611

Country of ref document: HK